Form 8-K - Current report
2024年2月13日 - 6:14AM
Edgar (US Regulatory)
false
0001870404
0001870404
2024-02-08
2024-02-08
0001870404
PBAX:ClassCommonStockParValue0.0001PerShareMember
2024-02-08
2024-02-08
0001870404
PBAX:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockMember
2024-02-08
2024-02-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 8, 2024
PHOENIX BIOTECH ACQUISITION CORP.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-40877 |
|
87-1088814 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification Number) |
2201 Broadway, Suite 705, Oakland, CA |
|
94612 |
(Address of principal executive offices) |
|
(Zip Code) |
(215) 731-9450
Registrant’s telephone number, including
area code
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☒ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Class A common stock, par value $0.0001 per share |
|
CERO |
|
NASDAQ Global Market |
Warrants, each whole warrant exercisable for one share of Class A common stock |
|
CEROW |
|
NASDAQ Global Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On February 8, 2024,
Phoenix Biotech Acquisition Corp., a Delaware corporation (the “Company”), held a special meeting with its stockholders (the
“Special Meeting”) at 11:00 a.m. Eastern Time for the purposes of considering and voting upon the proposals below (the “Proposals”).
As of the record date of January 17, 2024, there were a total of 6,234,582 shares of Class A common stock, par value $0.0001 per share
(the “Class A common stock”) issued and outstanding and entitled to vote at the Special Meeting. Proxies were received for
5,504,226 shares of common stock, or approximately 88.3% of the shares issued and outstanding and entitled to vote at the Special Meeting,
representing a quorum. Capitalized terms used, but not defined herein, shall have the meaning set forth in the Company’s Definitive Proxy Statement on
Schedule 14A filed with the Securities and Exchange Commission on January 22, 2024.
| Proposal 1. | To (a) adopt and approve the Business Combination
Agreement, pursuant to which Merger Sub will merge with and into CERo, with CERo surviving the merger as a wholly-owned subsidiary of
the Company and (b) approve such merger and the other transactions contemplated by the Business Combination Agreement, and (c) adopt
and approve each Ancillary Document (as defined in the Business Combination Agreement) to which the Company is a party and approve all
transactions contemplated therein. |
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,678 |
|
10,588 |
|
0 |
| Proposal 2. | To approve a proposed second amended and restated certificate
of incorporation for New CERo (the “Proposed Charter”) and second amended and restated bylaws for New CERo, which will be
in effect upon the closing of the Business Combination. |
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,678 |
|
10,588 |
|
0 |
| Proposal 3. | To approve, on a non-binding advisory basis, the following material
differences between the Proposed Charter and PBAX’s amended and restated certificate of incorporation, as amended from time to
time, which were presented as seven separate subproposals: |
(a) Advisory Charter Proposal A —
to change the corporate name of New CERo to “CERo Therapeutics Holdings, Inc.” on and from the time of the Business Combination;
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,678 |
|
10,588 |
|
0 |
(b) Advisory Charter Proposal B —
to increase New CERo’s capitalization so that it will have 1,000,000,000 authorized shares of a single class of common stock and
10,000,000 authorized shares of preferred stock;
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,666 |
|
10,600 |
|
0 |
(c) Advisory Charter Proposal C —
to create a classified board of directors consisting of three classes, Class I, Class II and Class III, with members of each class elected
for three-year terms expiring in sequential years;
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,666 |
|
10,600 |
|
0 |
(d) Advisory Charter Proposal D —
to provide that certain amendments to provisions of the Proposed Charter will require the approval of at least 66 2/3% of New CERo’s
then-outstanding shares of capital stock entitled to vote on such amendment and of each class entitled to vote thereon as a class;
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,666 |
|
10,600 |
|
0 |
(e) Advisory Charter Proposal E —
to make New CERo’s corporate existence perpetual instead of requiring PBAX to be dissolved and liquidated by April 8, 2024 (or such
later date as may be approved by PBAX’s stockholders), and to omit from the Proposed Charter the various provisions applicable only
to special purpose acquisition companies; and
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,678 |
|
10,588 |
|
0 |
(f) Advisory Charter Proposal F —
to remove the provision that allows stockholders to act by written consent as opposed to holding a stockholders meeting.
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,678 |
|
10,588 |
|
0 |
| Proposal 4. | To approve, for purposes of complying with the applicable provisions
of Nasdaq Listing Rule 5635, the issuance of shares of Class A common stock to CERo shareholders pursuant to the Business Combination
Agreement, including the potential issuance of an additional 1,200,000 earnout shares of Class A common stock. |
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,678 |
|
10,588 |
|
0 |
| Proposal 5. | To approve the appointment of five directors who, upon consummation
of the Business Combination, will become directors of New CERo. |
(1) Michael Byrnes
FOR |
|
ABSTAIN |
|
AGAINST |
5,504,254 |
|
12 |
|
0 |
(2) Brian Atwood
FOR |
|
ABSTAIN |
|
AGAINST |
5,504,254 |
|
12 |
|
0 |
(3) Kathleen LaPorte
FOR |
|
ABSTAIN |
|
AGAINST |
5,504,266 |
|
0 |
|
0 |
(4) Daniel Corey
FOR |
|
ABSTAIN |
|
AGAINST |
5,504,254 |
|
12 |
|
0 |
(5) Chris Ehrlich
FOR |
|
ABSTAIN |
|
AGAINST |
5,504,254 |
|
12 |
|
0 |
| Proposal 6. | To approve the 2024 Equity Incentive Plan, which will become
effective as of and contingent on the consummation of the Business Combination. |
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,678 |
|
10,588 |
|
0 |
| Proposal 7. | To approve the 2024 Employee Stock Purchase Plan, which will
become effective as of and contingent on the consummation of the Business Combination. |
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,678 |
|
10,588 |
|
0 |
| Proposal 8. | To approve a proposal to adjourn the Special Meeting to a later
date or dates if it is determined that more time is necessary or appropriate, in the judgment of the Company’s board of directors
or the officer presiding over the special meeting, for the Company to consummate the Business Combination. |
FOR |
|
ABSTAIN |
|
AGAINST |
5,493,666 |
|
10,600 |
|
0 |
Proposal 8 was not presented
to the stockholders because the foregoing resolutions to approve the consummation of the Business Combination were approved.
Item 8.01. Other
Events.
In connection with
the Special Meeting, holders of 671,285 shares of the Class A common stock exercised redemption rights and will be paid an aggregate
of $7,456,463.30 (or $11.11 per redeemed share).
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PHOENIX BIOTECH ACQUISITION CORP. |
|
|
|
|
By: |
/s/ Chris Ehrlich |
|
Name: |
Chris Ehrlich |
|
Title: |
Chief Executive Officer |
|
Dated: February 12, 2024
4
v3.24.0.1
Cover
|
Feb. 08, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Feb. 08, 2024
|
Entity File Number |
001-40877
|
Entity Registrant Name |
PHOENIX BIOTECH ACQUISITION CORP.
|
Entity Central Index Key |
0001870404
|
Entity Tax Identification Number |
87-1088814
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2201 Broadway
|
Entity Address, Address Line Two |
Suite 705
|
Entity Address, City or Town |
Oakland
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94612
|
City Area Code |
(215)
|
Local Phone Number |
731-9450
|
Written Communications |
true
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Class A common stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Class A common stock, par value $0.0001 per share
|
Trading Symbol |
CERO
|
Security Exchange Name |
NASDAQ
|
Warrants, each whole warrant exercisable for one share of Class A common stock |
|
Title of 12(b) Security |
Warrants, each whole warrant exercisable for one share of Class A common stock
|
Trading Symbol |
CEROW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBAX_ClassCommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBAX_WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Phoenix Biotech Aquisition (NASDAQ:PBAXU)
過去 株価チャート
から 4 2024 まで 5 2024
Phoenix Biotech Aquisition (NASDAQ:PBAXU)
過去 株価チャート
から 5 2023 まで 5 2024